MedAdvisor Limited

As of June 30, 2024, MedAdvisor Limited has 550.54M shares outstanding.

As of June 30, 2024, MedAdvisor Limited trades at a trailing price-to-earnings ratio of 345.98. The price-to-sales ratio is 2.24, and the price-to-book ratio stands at 6.16.

As of June 30, 2024, MedAdvisor Limited trades at an EV/EBITDA multiple of 100.52 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.22 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 100.52 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. MedAdvisor Limited trades at an EV/FCF ratio of 77.70, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2024, MedAdvisor Limited maintains a current ratio of 0.71, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.44, indicating elevated leverage, while an interest coverage ratio of 1.40 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2024, MedAdvisor Limited posted a return on equity (ROE) of 1.82, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.65 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.81, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.34, useful for judging operating efficiency across full business cycles.

These figures cover the twelve months ended June 30, 2024. That works out to an effective tax rate of 14.23, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

Over the twelve months ended June 30, 2024, MedAdvisor Limited posted a gross margin of 60.81, reflecting its pricing power and cost economics. The operating margin of 2.21 and net profit margin of 0.65 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Free cash flow yield stands at 0.60, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.30, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to MedAdvisor Limited shareholders.

MedAdvisor Limited's most recent stock split took place on November 12, 2020 with a 500:507 split ratio.

As of June 30, 2024, MedAdvisor Limited has an Altman Z-Score of 3.90, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.